Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.

Ryan CW, Stadler WM, Vogelzang NJ. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005 May; 95(7):963-8.

View in: PubMed

collapse authors with profiles